Results 221 to 230 of about 180,290 (312)

Neoadjuvant Cemiplimab for Resectable Locoregionally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series

Head &Neck, EarlyView.
ABSTRACT Introduction A Phase II trial demonstrated that neoadjuvant cemiplimab was associated with pathologic complete response (pCR) in 51% of patients with locoregionally advanced cutaneous squamous cell carcinoma (cuSCC). We evaluated real‐world radiographic and pathologic responses to neoadjuvant cemiplimab and assessed radiologic–pathologic ...
Whitney Jin, Ryan K. Rigsby, Kim Ely, Austin Hoke, Robert Sinard, Kyle Mannion, Jill Gilbert, Lindsay Mundy, Alexander Langerman, Sarah Rohde, Barbara Murphy, Eben Rosenthal, Mitra Mehrad, Michael C. Topf, Jennifer H. Choe   +14 more
wiley   +1 more source

Structure-Based Virtual Screening and Mechanistic Characterization of Methotrexate and Selinexor as Potent Anti-Melanogenic Agents via Multi-Pathway Suppression of MITF. [PDF]

Cells
Zhang Z, Li H, Shi Z, Bai X, Yin P, Yang L.   +5 more
europepmc   +1 more source

Atypical Vesicular Skin Eruption Following a Low-Dose Methotrexate Dosing Error: A Case Report. [PDF]

Cureus
London MGH, Frasier KM, Werpachowski NK, Scaduto J.   +3 more
europepmc   +1 more source

Case Report: Balancing immunosuppression and infection-intravenous immunoglobulin in anti-HMGCR immune-mediated necrotizing myopathy complicated by severe pneumonia. [PDF]

Front Med (Lausanne)
Fu J, Zhao Q, Lou JB, Tang GH, Chen W, Zhao JH, He QS.   +6 more
europepmc   +1 more source

Asymptomatic Cardiotoxicity After High‐Dose Anthracycline Treatment in Sarcoma Patients Assessed by Biomarkers and Echocardiography

International Journal of Cancer, EarlyView.
ABSTRACT Treatment of sarcoma includes high‐dose anthracyclines, which can cause cardiotoxicity. This study assesses the correlation of cardiac biomarkers and echocardiographic parameters on asymptomatic cardiotoxicity in sarcoma patients treated with anthracyclines.
Elissa A. S. Polomski, Frank M. Speetjens, J. Wouter Jukema, Julius C. Heemelaar, Michiel A. J. van de Sande, Hans Gelderblom, M. Louisa Antoni   +6 more
wiley   +1 more source

Contemporary management of sarcoidosis. [PDF]

Front Med (Lausanne)
Khine NW, Fletcher S.
europepmc   +1 more source

Tolerability of Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: A Real‐World Study

International Journal of Cancer, EarlyView.
ABSTRACT Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate‐577 trial, Grade 3–5 nivolumab‐related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real‐world data on immunotherapy‐related adverse
Michelle Koops van ’t Jagt, Anniek Strijdhorst, Tamara Jessica Huizer, Esther Albertien Kleibeuker, Sarah Derks, Bianca Mostert, Hanneke van Laarhoven, Jacco Juri de Haan   +7 more
wiley   +1 more source

Clinical practice guideline for psoriasis management in Latin America. [PDF]

An Bras Dermatol
Valenzuela F, Castro Ayarza JR, Kaplan D, Londoño-García AM, Macías García KDR, Magariños G, Rivas Záldivar ES, Franco M, Cano S, Cortés C, Cárdenas PJ, Castro C, Ferreira R, Martínez S, Ibatá Bernal L, Castillo JC, Ospina J.   +16 more
europepmc   +1 more source

Longitudinal AMH trajectories, ovarian reserve recovery, and fertility outcomes after multiagent chemotherapy for high‐risk gestational trophoblastic neoplasia: A real‐world cohort study

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective To characterize anti‐Müllerian hormone (AMH) recovery after multiagent chemotherapy for high‐risk gestational trophoblastic neoplasia (GTN) and evaluate the impact of regimen and hysterectomy. Methods This was a retrospective cohort of 68 high‐risk GTN patients treated with EMA/CO (etoposide, methotrexate, actinomycin D ...
Wei Xue, Tianyi Chen, Yuxiao Wu, Tong Ren, Jun Zhao, Fengzhi Feng, Xirun Wan, Yang Xiang, Junjun Yang   +8 more
wiley   +1 more source

Medicine Requirements and Budget Implication for Pediatric Acute Lymphoblastic Leukemia in Indonesia: A Morbidity-Based Approach. [PDF]

Risk Manag Healthc Policy
Argadiredja DNS, Alfaqeeh M, Fatinah Y, Gatera VA, Andalusia LR, Sinuraya RK, Abushanab D, Abdulah R, Suwantika AA.   +8 more
europepmc   +1 more source